SMi Drug Discovery Market Research Report

Company Overview

Name: SMi Drug Discovery Limited

Mission: SMi is developing transformational, single molecule imaging technologies for biomedical research and diagnostics. Their mission focuses on using advanced optics and deep learning to enable direct observation and quantification of individual molecules, thus empowering influential scientific research and healthcare.

Founded: 2018

Founders:

Dr. Andrew Thompson

Professor James Brozik

James Clark

Key People:

Dr. Andrew Thompson (Chief Executive Officer & Co-Founder)

Professor James Brozik (Chief Scientific Officer & Co-Founder)

James Clark (Chief Financial Officer & Co-Founder)

Stephen Reeder (Chief Operating Officer)

Michael Risley (Chief Development Officer)

Dr. John Hirst CBE (Non-Executive Director & Chair)

Dr. Stephen Little (Non-Executive Director)

Dr. David Onions (Norcliffe Capital Board Observer)

Dr. Stefan Hamill (Vice President Strategy)

Headquarters: Cambridge, UK.

Number of Employees: No information is available

Revenue: No information is available

Known For: SMi is known for pioneering single molecule imaging, a technology integral in biomedical research and diagnostic advancements. Their platform is especially recognized for enabling unprecedented quantification and rapid analysis of individual molecules.

Products

Core Technology Platform

Components:

Benchtop Instrument

Consumables

Analytical Software

Description: SMi offers a platform that integrates an instrument, consumables, and software into a single system providing an automated workflow with super-resolution detection capabilities.

Key Features:

Automates imaging and analysis, streamlining complex procedures.

Detects and quantifies molecular interactions.

Supports multiple molecular targets and high-throughput formats.

Requires minimal training for operation.

Application Areas

Biomedical Research:

Description: Facilitates drug discovery by providing quantitative data about single molecules, critical for identifying, optimizing, and characterizing drug candidates.

Key Features: Single molecule resolution, high throughput screening, and low material consumption.

Diagnosis:

Description: revolutionary technology offering unprecedented resolution and sensitivity, transforming molecular diagnostics.

Key Features: Rapid, cost-effective, and multipurpose platform capable of processing hundreds of samples within minutes.

Recent Developments

Grant Funding: SMi received several significant grants, including prestigious awards from Innovate UK and CPI, supporting the development of cancer diagnosis technology and regulatory processes.

New Partnerships:

Collaborations with Medicines Discovery Catapult for cancer diagnosis technology.

Partnerships with University of Cambridge for advanced biomedical research.

Patent Achievements:

Secured patents for its super-resolution optical technology in the UK and Hong Kong.

New Appointments: Appointed Stefan Hamill as VP of Strategy to drive commercialization.

Conclusion

SMi Drug Discovery continues to push the boundaries in single molecule imaging, paving the way for transformative scientific and medical advancements. Through strategic partnerships, cutting-edge technology, and a commitment to innovation, SMi is positioned as a leader in advancing research and diagnostics capabilities. Prominent grants and strategic appointments reinforcing their market position, alongside robust research endeavors with esteemed institutions, underline SMi's continuous trajectory of growth and influence in the life sciences sector.